NCT01697319
MPS IVA, Morquio A Syndrome, Mucopolysaccharidosis IVA
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.
All
From 5 Years
No
BMN 110
Phase 2
Interventional
16
2012-08
2016-01-12
Oakland, California, United States
Chicago, Illinois, United States
Hamburg, , Germany
Mainz, , Germany
Birmingham, , United Kingdom
Manchester, , United Kingdom
Salford, , United Kingdom
*required fields
"*" indicates required fields